Corcept Therapeutics (CORT) Amortization of Deferred Charges (2016 - 2021)
Corcept Therapeutics' Amortization of Deferred Charges history spans 9 years, with the latest figure at $508000.0 for Q4 2021.
- On a quarterly basis, Amortization of Deferred Charges rose 4.96% to $508000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $2.0 million, a 16.53% increase, with the full-year FY2021 number at $2.0 million, up 16.53% from a year prior.
- Amortization of Deferred Charges hit $508000.0 in Q4 2021 for Corcept Therapeutics, up from $502000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for CORT hit a ceiling of $508000.0 in Q4 2021 and a floor of $3000.0 in Q3 2017.
- Historically, Amortization of Deferred Charges has averaged $345933.3 across 4 years, with a median of $385000.0 in 2020.
- Biggest five-year swings in Amortization of Deferred Charges: tumbled 40.0% in 2017 and later skyrocketed 45.78% in 2020.
- Tracing CORT's Amortization of Deferred Charges over 4 years: stood at $3000.0 in 2017, then skyrocketed by 10966.67% to $332000.0 in 2019, then skyrocketed by 45.78% to $484000.0 in 2020, then grew by 4.96% to $508000.0 in 2021.
- Business Quant data shows Amortization of Deferred Charges for CORT at $508000.0 in Q4 2021, $502000.0 in Q3 2021, and $496000.0 in Q2 2021.